Clinical Trials Browser

Phase 1 × INDUSTRY × catumaxomab × Clear all

NCT04819399 2022-04-05

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Phase 1 Unknown

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01320020 2013-07-02

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

Phase 1 Terminated

Carcinoma, Neoplasms